TELA Bio Inc Stock News

MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three...

MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 37th Annual Healthcare Conference.

MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to ...

TELA Bio, Inc. ( TELA ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Antony Koblish - Co-founder, CEO & Director Jeffrey Blizard - President of TELA Bio & Director Roberto Cuca - CFO & COO Jim Hagen Conference Call Participants Louisa Smith - Gilmartin Group LLC Caitlin Cronin - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, ...

MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-fun...

MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025.

MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of ...

TELA Bio, Inc. (NASDAQ:TELA ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Antony Koblish - Co-founder, CEO & Director Jeffrey Blizard - President of TELA Bio & Director Roberto E. Cuca - CFO & COO Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division...